With the help of Delphi Ventures and TPG Biotech, Bothell, WA-based Alder Biopharmaceuticals gained $40 million in its third round round of financing. Sevin Rosen Funds, Ventures West, H.I.G. Ventures, and WRF Capital also contributed to the round. Alder identifies, develops, and manufactures antibody therapeutics to treat autoimmune and inflammatory diseases.
"This financing will allow Alder to rapidly advance our lead antibody therapeutic ALD518 through multiple proof-of-concept trials, broaden our product pipeline, and continue to build on our proprietary antibody discovery and manufacturing technologies."
- see this release for more
ALSO: California-based ViOptix raised $12.2 million in a Series D round of financing. Report